Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Natera announced the publication of data in JAMA Oncology demonstrating that its Signatera test predicts overall survival benefit from adjuvant chemotherapy in patients with resected metastatic colorectal cancer. The study of 298 patients found that MRD-positive patients who received chemotherapy had significantly improved overall survival compared to observation, while MRD-negative patients derived no significant benefit.
Key figures
- Cohort size
- 298
- Os hazard ratio
- 0.27
- Dfs hazard ratio
- 0.07
- Follow up months
- 43
- Os 48 month act vs obs
- 65.3% vs. 32.9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.